Lyme disease is the most common tick-borne illness in the United States. Many signs and symptoms of the disease are similar to other conditions so diagnosis can be challenging; however, individuals immediately treated for the disease usually recover rapidly and completely.
The BioPlex 2200 Lyme Total Assay can simultaneously detect multiple targets, providing laboratories valuable information in the early stages of Lyme disease so patients are able to receive treatment as quickly as possible.
Bio-Rad said the release of the BioPlex 2200 Lyme Total assay is the latest offering in Bio-Rad's infectious disease menu for the BioPlex 2200 System, an automated multiplex technology platform.
The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or "multiplex" multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.
Bio-Rad Laboratories is in developing, manufacturing, and marketing a range of innovative products for the life science research and clinical diagnostic markets.
With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare.
Its customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality.
Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding USD 2.2bn in 2018.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial